These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vasopeptidase inhibition: a new concept in blood pressure management. Burnett JC J Hypertens Suppl; 1999 Feb; 17(1):S37-43. PubMed ID: 10340842 [TBL] [Abstract][Full Text] [Related]
6. Vasopeptidase inhibitors, neutral endopeptidase inhibitors, and dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Nawarskas J; Rajan V; Frishman WH Heart Dis; 2001; 3(6):378-85. PubMed ID: 11975822 [TBL] [Abstract][Full Text] [Related]
7. Vasopeptidase inhibition: a double-edged sword? Campbell DJ Hypertension; 2003 Mar; 41(3):383-9. PubMed ID: 12623931 [TBL] [Abstract][Full Text] [Related]
8. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. Daull P; Jeng AY; Battistini B J Cardiovasc Pharmacol; 2007 Sep; 50(3):247-56. PubMed ID: 17878751 [TBL] [Abstract][Full Text] [Related]
9. Vasopeptidase inhibitors: will they have a role in clinical practice? Worthley MI; Corti R; Worthley SG Br J Clin Pharmacol; 2004 Jan; 57(1):27-36. PubMed ID: 14678337 [TBL] [Abstract][Full Text] [Related]
10. Vasopeptidase inhibitors: potential role in the treatment of heart failure. Trindade PT; Rouleau JL Heart Fail Monit; 2001; 2(1):2-7. PubMed ID: 12634892 [TBL] [Abstract][Full Text] [Related]
11. Vasopeptidase inhibition and endothelial function in hypertension. d'Uscio LV; Lüscher TF Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S6-14. PubMed ID: 11716800 [TBL] [Abstract][Full Text] [Related]
12. Effects of omapatrilat on pharmacodynamic biomarkers of neutral endopeptidase and Angiotensin-converting enzyme activity in humans. Vesterqvist O; Reeves RA Curr Hypertens Rep; 2001 Dec; 3 Suppl 2():S22-7. PubMed ID: 11716802 [TBL] [Abstract][Full Text] [Related]
13. Effects of neutral endopeptidase inhibition and combined angiotensin converting enzyme and neutral endopeptidase inhibition on angiotensin and bradykinin peptides in rats. Campbell DJ; Anastasopoulos F; Duncan AM; James GM; Kladis A; Briscoe TA J Pharmacol Exp Ther; 1998 Nov; 287(2):567-77. PubMed ID: 9808682 [TBL] [Abstract][Full Text] [Related]
14. Vasopeptidase inhibition: a novel approach to cardiovascular therapy. Floras JS Can J Cardiol; 2002 Feb; 18(2):177-82. PubMed ID: 11875587 [TBL] [Abstract][Full Text] [Related]
15. Current role of neprilysin inhibitors in hypertension and heart failure. von Lueder TG; Atar D; Krum H Pharmacol Ther; 2014 Oct; 144(1):41-9. PubMed ID: 24836726 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo. Ferro CJ; Spratt JC; Haynes WG; Webb DJ Circulation; 1998 Jun; 97(23):2323-30. PubMed ID: 9639376 [TBL] [Abstract][Full Text] [Related]